Synergy of immune checkpoint inhibitors and biomarker discovery validated in 3D tumor microenvironment model
[by Lee, Young Sung] The results of the joint research conducted by SillaJen and Qureator on the anticancer drug candidate 'BAL0891' were presented at the American Association for Cancer Research Annual Conference (AACR 2025) held in Chicago, Illinois, on the afternoon of April 28 (local time). Qureator, based in San Diego, California, is a biotechnology company specializing in advanced 3D organoid research.
In June 2024, both parties entered into a joint research agreement aimed at exploring the development strategy of 먹튀없는 바카라사이트 아톰카지노. The collaboration focuses on evaluating the synergistic effects of 먹튀없는 바카라사이트 아톰카지노 in combination with immunotherapy drugs and identifying potential biomarkers using Qureator’s 3D TIME (3D Tumor Immune Microenvironment) model.
The first study assessed the therapeutic efficacy of BAL0891 in combination with anti-PD-1 antibodies. Using tumor samples derived from cancer patients, BAL0891 alone was found to induce an anticancer immune response in a 3D tumor microenvironment model designed to replicate the human tumor environment. Moreover, when administered in combination with an anti-PD-1 antibody, the immune response was further amplified, resulting in a pronounced cancer cell killing effect. In particular, the same synergy effect was also observed in models resistant to anti-PD-1 antibodies, suggesting that BAL0891 may offer a potential strategy to overcome such resistance, an aspect 먹튀없는 바카라사이트 아톰카지노 particularly underscored.
The second study analyzed patient response heterogeneity to 먹튀없는 바카라사이트 아톰카지노 using a 3D tumor model constructed from tumor samples of patients with various cancer types. This approach enabled the identification of a predictive biomarker capable of distinguishing patient groups likely to respond to 먹튀없는 바카라사이트 아톰카지노 treatment. The findings provide evidence supporting the feasibility of patient selection and the development of personalized combination treatment strategies (patient stratification) based on biomarker-driven selection.
This announcement garnered significant attention, particularly as it followed the U.S. Food and Drug Administration’s (FDA) recent declaration to phase out animal testing. In the wake of the FDA’s decision, organoid-based research has gained global attention, and the joint study by 먹튀없는 바카라사이트 아톰카지노 and Qureator attracted notable interest within the local scientific communities.
Moving forward, 먹튀없는 바카라사이트 아톰카지노 plans to establish the optimal recommended Phase 2 clinical dose (RP2D) using an organoid-based pharmacokinetic-pharmacodynamic (PK-PD) modeling approach, drawing on the data obtained from this combination therapy study.
“The research findings by 먹튀없는 바카라사이트 아톰카지노 and Qureator are meaningful in their own right and hold special meaning as they involve organoid-based research, a field that has recently gained momentum in both the United States and Europe,” a 먹튀없는 바카라사이트 아톰카지노 official stated.